調査レポート | • レポートコード：GIR-2104Z11753 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、102ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥494,160 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥741,240 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥988,320 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、希少血友病因子のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。希少血友病因子の種類別市場規模（第I因子、第II因子、第V因子、第VII因子、第X因子、第XI因子、第XIII因子）、用途別市場規模（因子濃縮物、新鮮凍結血漿、寒冷沈降物、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・希少血友病因子の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Novo Nordisk、Biogen、Bayer healthcare、Pfizer, Inc.、Baxalta、CSL Behring、Bio Products Laboratory Ltd. ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：第I因子、第II因子、第V因子、第VII因子、第X因子、第XI因子、第XIII因子 ・用途別分析2016年-2026年：因子濃縮物、新鮮凍結血漿、寒冷沈降物、その他 ・希少血友病因子の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・希少血友病因子のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・希少血友病因子のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・希少血友病因子の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・希少血友病因子の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Rare Hemophilia Factors market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Rare Hemophilia Factors size is estimated to be USD 231 million in 2025 from USD 207.1 million in 2019, with a change XX% between 2019 and 2020. The global Rare Hemophilia Factors market size is expected to grow at a CAGR of 2.8% for the next five years.
Market segmentation
Rare Hemophilia Factors market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Factor I
Factor II
Factor V
Factor VII
Factor X
Factor XI
Factor XIII
Market segment by Application, can be divided into
Factor Concentrates
Fresh Frozen Plasma
Cryoprecipitate
Others
Market segment by players, this report covers
Novo Nordisk
Biogen
Bayer healthcare
Pfizer, Inc.
Baxalta
CSL Behring
Bio Products Laboratory Ltd.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Rare Hemophilia Factors
1.2 Classification of Rare Hemophilia Factors by Type
1.2.1 Overview: Global Rare Hemophilia Factors Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Rare Hemophilia Factors Revenue Market Share by Type in 2020
1.2.3 Factor I
1.2.4 Factor II
1.2.5 Factor V
1.2.6 Factor VII
1.2.7 Factor X
1.2.8 Factor XI
1.2.9 Factor XIII
1.3 Global Rare Hemophilia Factors Market by Application
1.3.1 Overview: Global Rare Hemophilia Factors Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Factor Concentrates
1.3.3 Fresh Frozen Plasma
1.3.4 Cryoprecipitate
1.3.5 Others
1.4 Global Rare Hemophilia Factors Market Size & Forecast
1.5 Global Rare Hemophilia Factors Market Size and Forecast by Region
1.5.1 Global Rare Hemophilia Factors Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Rare Hemophilia Factors Market Size by Region, (2016-2021)
1.5.3 North America Rare Hemophilia Factors Market Size and Prospect (2016-2026)
1.5.4 Europe Rare Hemophilia Factors Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Rare Hemophilia Factors Market Size and Prospect (2016-2026)
1.5.6 South America Rare Hemophilia Factors Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Rare Hemophilia Factors Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Rare Hemophilia Factors Market Drivers
1.6.2 Rare Hemophilia Factors Market Restraints
1.6.3 Rare Hemophilia Factors Trends Analysis
2 Company Profiles
2.1 Novo Nordisk
2.1.1 Novo Nordisk Details
2.1.2 Novo Nordisk Major Business
2.1.3 Novo Nordisk Rare Hemophilia Factors Product and Solutions
2.1.4 Novo Nordisk Rare Hemophilia Factors Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Novo Nordisk Recent Developments and Future Plans
2.2 Biogen
2.2.1 Biogen Details
2.2.2 Biogen Major Business
2.2.3 Biogen Rare Hemophilia Factors Product and Solutions
2.2.4 Biogen Rare Hemophilia Factors Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Biogen Recent Developments and Future Plans
2.3 Bayer healthcare
2.3.1 Bayer healthcare Details
2.3.2 Bayer healthcare Major Business
2.3.3 Bayer healthcare Rare Hemophilia Factors Product and Solutions
2.3.4 Bayer healthcare Rare Hemophilia Factors Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Bayer healthcare Recent Developments and Future Plans
2.4 Pfizer, Inc.
2.4.1 Pfizer, Inc. Details
2.4.2 Pfizer, Inc. Major Business
2.4.3 Pfizer, Inc. Rare Hemophilia Factors Product and Solutions
2.4.4 Pfizer, Inc. Rare Hemophilia Factors Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Pfizer, Inc. Recent Developments and Future Plans
2.5 Baxalta
2.5.1 Baxalta Details
2.5.2 Baxalta Major Business
2.5.3 Baxalta Rare Hemophilia Factors Product and Solutions
2.5.4 Baxalta Rare Hemophilia Factors Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Baxalta Recent Developments and Future Plans
2.6 CSL Behring
2.6.1 CSL Behring Details
2.6.2 CSL Behring Major Business
2.6.3 CSL Behring Rare Hemophilia Factors Product and Solutions
2.6.4 CSL Behring Rare Hemophilia Factors Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 CSL Behring Recent Developments and Future Plans
2.7 Bio Products Laboratory Ltd.
2.7.1 Bio Products Laboratory Ltd. Details
2.7.2 Bio Products Laboratory Ltd. Major Business
2.7.3 Bio Products Laboratory Ltd. Rare Hemophilia Factors Product and Solutions
2.7.4 Bio Products Laboratory Ltd. Rare Hemophilia Factors Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Bio Products Laboratory Ltd. Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Rare Hemophilia Factors Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Rare Hemophilia Factors Players Market Share
3.2.2 Top 10 Rare Hemophilia Factors Players Market Share
3.2.3 Market Competition Trend
3.3 Rare Hemophilia Factors Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Rare Hemophilia Factors Revenue and Market Share by Type (2016-2021)
4.2 Global Rare Hemophilia Factors Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Rare Hemophilia Factors Revenue Market Share by Application (2016-2021)
5.2 Rare Hemophilia Factors Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Rare Hemophilia Factors Revenue by Type (2016-2026)
6.2 North America Rare Hemophilia Factors Revenue by Application (2016-2026)
6.3 North America Rare Hemophilia Factors Market Size by Country
6.3.1 North America Rare Hemophilia Factors Revenue by Country (2016-2026)
6.3.2 United States Rare Hemophilia Factors Market Size and Forecast (2016-2026)
6.3.3 Canada Rare Hemophilia Factors Market Size and Forecast (2016-2026)
6.3.4 Mexico Rare Hemophilia Factors Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Rare Hemophilia Factors Revenue by Type (2016-2026)
7.2 Europe Rare Hemophilia Factors Revenue by Application (2016-2026)
7.3 Europe Rare Hemophilia Factors Market Size by Country
7.3.1 Europe Rare Hemophilia Factors Revenue by Country (2016-2026)
7.3.2 Germany Rare Hemophilia Factors Market Size and Forecast (2016-2026)
7.3.3 France Rare Hemophilia Factors Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Rare Hemophilia Factors Market Size and Forecast (2016-2026)
7.3.5 Russia Rare Hemophilia Factors Market Size and Forecast (2016-2026)
7.3.6 Italy Rare Hemophilia Factors Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Rare Hemophilia Factors Revenue by Type (2016-2026)
8.2 Asia-Pacific Rare Hemophilia Factors Revenue by Application (2016-2026)
8.3 Asia-Pacific Rare Hemophilia Factors Market Size by Region
8.3.1 Asia-Pacific Rare Hemophilia Factors Revenue by Region (2016-2026)
8.3.2 China Rare Hemophilia Factors Market Size and Forecast (2016-2026)
8.3.3 Japan Rare Hemophilia Factors Market Size and Forecast (2016-2026)
8.3.4 South Korea Rare Hemophilia Factors Market Size and Forecast (2016-2026)
8.3.5 India Rare Hemophilia Factors Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Rare Hemophilia Factors Market Size and Forecast (2016-2026)
8.3.7 Australia Rare Hemophilia Factors Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Rare Hemophilia Factors Revenue by Type (2016-2026)
9.2 South America Rare Hemophilia Factors Revenue by Application (2016-2026)
9.3 South America Rare Hemophilia Factors Market Size by Country
9.3.1 South America Rare Hemophilia Factors Revenue by Country (2016-2026)
9.3.2 Brazil Rare Hemophilia Factors Market Size and Forecast (2016-2026)
9.3.3 Argentina Rare Hemophilia Factors Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Rare Hemophilia Factors Revenue by Type (2016-2026)
10.2 Middle East & Africa Rare Hemophilia Factors Revenue by Application (2016-2026)
10.3 Middle East & Africa Rare Hemophilia Factors Market Size by Country
10.3.1 Middle East & Africa Rare Hemophilia Factors Revenue by Country (2016-2026)
10.3.2 Turkey Rare Hemophilia Factors Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Rare Hemophilia Factors Market Size and Forecast (2016-2026)
10.3.4 UAE Rare Hemophilia Factors Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Rare Hemophilia Factors Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Rare Hemophilia Factors Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Rare Hemophilia Factors Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Rare Hemophilia Factors Revenue (USD Million) by Region (2016-2021)
Table 5. Global Rare Hemophilia Factors Revenue Market Share by Region (2021-2026)
Table 6. Novo Nordisk Corporate Information, Head Office, and Major Competitors
Table 7. Novo Nordisk Major Business
Table 8. Novo Nordisk Rare Hemophilia Factors Product and Solutions
Table 9. Novo Nordisk Rare Hemophilia Factors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Biogen Corporate Information, Head Office, and Major Competitors
Table 11. Biogen Major Business
Table 12. Biogen Rare Hemophilia Factors Product and Solutions
Table 13. Biogen Rare Hemophilia Factors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Bayer healthcare Corporate Information, Head Office, and Major Competitors
Table 15. Bayer healthcare Major Business
Table 16. Bayer healthcare Rare Hemophilia Factors Product and Solutions
Table 17. Bayer healthcare Rare Hemophilia Factors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Pfizer, Inc. Corporate Information, Head Office, and Major Competitors
Table 19. Pfizer, Inc. Major Business
Table 20. Pfizer, Inc. Rare Hemophilia Factors Product and Solutions
Table 21. Pfizer, Inc. Rare Hemophilia Factors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Baxalta Corporate Information, Head Office, and Major Competitors
Table 23. Baxalta Major Business
Table 24. Baxalta Rare Hemophilia Factors Product and Solutions
Table 25. Baxalta Rare Hemophilia Factors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. CSL Behring Corporate Information, Head Office, and Major Competitors
Table 27. CSL Behring Major Business
Table 28. CSL Behring Rare Hemophilia Factors Product and Solutions
Table 29. CSL Behring Rare Hemophilia Factors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Bio Products Laboratory Ltd. Corporate Information, Head Office, and Major Competitors
Table 31. Bio Products Laboratory Ltd. Major Business
Table 32. Bio Products Laboratory Ltd. Rare Hemophilia Factors Product and Solutions
Table 33. Bio Products Laboratory Ltd. Rare Hemophilia Factors Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Global Rare Hemophilia Factors Revenue (USD Million) by Players (2019-2021)
Table 35. Global Rare Hemophilia Factors Revenue Share by Players (2019-2021)
Table 36. Breakdown of Rare Hemophilia Factors by Company Type (Tier 1, Tier 2 and Tier 3)
Table 37. Rare Hemophilia Factors Players Head Office, Products and Services Provided
Table 38. Rare Hemophilia Factors Mergers & Acquisitions in the Past Five Years
Table 39. Rare Hemophilia Factors New Entrants and Expansion Plans
Table 40. Global Rare Hemophilia Factors Revenue (USD Million) by Type (2016-2021)
Table 41. Global Rare Hemophilia Factors Revenue Share by Type (2016-2021)
Table 42. Global Rare Hemophilia Factors Revenue Forecast by Type (2021-2026)
Table 43. Global Rare Hemophilia Factors Revenue by Application (2016-2021)
Table 44. Global Rare Hemophilia Factors Revenue Forecast by Application (2021-2026)
Table 45. North America Rare Hemophilia Factors Revenue by Type (2016-2021) & (USD Million)
Table 46. North America Rare Hemophilia Factors Revenue by Type (2021-2026) & (USD Million)
Table 47. North America Rare Hemophilia Factors Revenue by Application (2016-2021) & (USD Million)
Table 48. North America Rare Hemophilia Factors Revenue by Application (2021-2026) & (USD Million)
Table 49. North America Rare Hemophilia Factors Revenue by Country (2016-2021) & (USD Million)
Table 50. North America Rare Hemophilia Factors Revenue by Country (2021-2026) & (USD Million)
Table 51. Europe Rare Hemophilia Factors Revenue by Type (2016-2021) & (USD Million)
Table 52. Europe Rare Hemophilia Factors Revenue by Type (2021-2026) & (USD Million)
Table 53. Europe Rare Hemophilia Factors Revenue by Application (2016-2021) & (USD Million)
Table 54. Europe Rare Hemophilia Factors Revenue by Application (2021-2026) & (USD Million)
Table 55. Europe Rare Hemophilia Factors Revenue by Country (2016-2021) & (USD Million)
Table 56. Europe Rare Hemophilia Factors Revenue by Country (2021-2026) & (USD Million)
Table 57. Asia-Pacific Rare Hemophilia Factors Revenue by Type (2016-2021) & (USD Million)
Table 58. Asia-Pacific Rare Hemophilia Factors Revenue by Type (2021-2026) & (USD Million)
Table 59. Asia-Pacific Rare Hemophilia Factors Revenue by Application (2016-2021) & (USD Million)
Table 60. Asia-Pacific Rare Hemophilia Factors Revenue by Application (2021-2026) & (USD Million)
Table 61. Asia-Pacific Rare Hemophilia Factors Revenue by Region (2016-2021) & (USD Million)
Table 62. Asia-Pacific Rare Hemophilia Factors Revenue by Region (2021-2026) & (USD Million)
Table 63. South America Rare Hemophilia Factors Revenue by Type (2016-2021) & (USD Million)
Table 64. South America Rare Hemophilia Factors Revenue by Type (2021-2026) & (USD Million)
Table 65. South America Rare Hemophilia Factors Revenue by Application (2016-2021) & (USD Million)
Table 66. South America Rare Hemophilia Factors Revenue by Application (2021-2026) & (USD Million)
Table 67. South America Rare Hemophilia Factors Revenue by Country (2016-2021) & (USD Million)
Table 68. South America Rare Hemophilia Factors Revenue by Country (2021-2026) & (USD Million)
Table 69. Middle East & Africa Rare Hemophilia Factors Revenue by Type (2016-2021) & (USD Million)
Table 70. Middle East & Africa Rare Hemophilia Factors Revenue by Type (2021-2026) & (USD Million)
Table 71. Middle East & Africa Rare Hemophilia Factors Revenue by Application (2016-2021) & (USD Million)
Table 72. Middle East & Africa Rare Hemophilia Factors Revenue by Application (2021-2026) & (USD Million)
Table 73. Middle East & Africa Rare Hemophilia Factors Revenue by Country (2016-2021) & (USD Million)
Table 74. Middle East & Africa Rare Hemophilia Factors Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Rare Hemophilia Factors Picture
Figure 2. Global Rare Hemophilia Factors Revenue Market Share by Type in 2020
Figure 3. Factor I
Figure 4. Factor II
Figure 5. Factor V
Figure 6. Factor VII
Figure 7. Factor X
Figure 8. Factor XI
Figure 9. Factor XIII
Figure 10. Rare Hemophilia Factors Revenue Market Share by Application in 2020
Figure 11. Factor Concentrates Picture
Figure 12. Fresh Frozen Plasma Picture
Figure 13. Cryoprecipitate Picture
Figure 14. Others Picture
Figure 15. Global Rare Hemophilia Factors Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 16. Global Rare Hemophilia Factors Revenue and Forecast (2016-2026) & (USD Million)
Figure 17. Global Rare Hemophilia Factors Revenue Market Share by Region (2016-2026)
Figure 18. Global Rare Hemophilia Factors Revenue Market Share by Region in 2020
Figure 19. North America Rare Hemophilia Factors Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Europe Rare Hemophilia Factors Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Asia-Pacific Rare Hemophilia Factors Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. South America Rare Hemophilia Factors Revenue (USD Million) and Growth Rate (2016-2026)
Figure 23. Rare Hemophilia Factors Market Drivers
Figure 24. Rare Hemophilia Factors Market Restraints
Figure 25. Rare Hemophilia Factors Market Trends
Figure 26. Novo Nordisk Recent Developments and Future Plans
Figure 27. Biogen Recent Developments and Future Plans
Figure 28. Bayer healthcare Recent Developments and Future Plans
Figure 29. Pfizer, Inc. Recent Developments and Future Plans
Figure 30. Baxalta Recent Developments and Future Plans
Figure 31. CSL Behring Recent Developments and Future Plans
Figure 32. Bio Products Laboratory Ltd. Recent Developments and Future Plans
Figure 34. Global Rare Hemophilia Factors Revenue Share by Players in 2020
Figure 35. Rare Hemophilia Factors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 36. Global Top 3 Players Rare Hemophilia Factors Revenue Market Share in 2020
Figure 37. Global Top 10 Players Rare Hemophilia Factors Revenue Market Share in 2020
Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 39. Global Rare Hemophilia Factors Revenue Share by Type in 2020
Figure 40. Global Rare Hemophilia Factors Market Share Forecast by Type (2021-2026)
Figure 41. Global Rare Hemophilia Factors Revenue Share by Application in 2020
Figure 42. Global Rare Hemophilia Factors Market Share Forecast by Application (2021-2026)
Figure 43. North America Rare Hemophilia Factors Sales Market Share by Type (2016-2026)
Figure 44. North America Rare Hemophilia Factors Sales Market Share by Application (2016-2026)
Figure 45. North America Rare Hemophilia Factors Revenue Market Share by Country (2016-2026)
Figure 46. United States Rare Hemophilia Factors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Canada Rare Hemophilia Factors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Mexico Rare Hemophilia Factors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Europe Rare Hemophilia Factors Sales Market Share by Type (2016-2026)
Figure 50. Europe Rare Hemophilia Factors Sales Market Share by Application (2016-2026)
Figure 51. Europe Rare Hemophilia Factors Revenue Market Share by Country (2016-2026)
Figure 52. Germany Rare Hemophilia Factors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. France Rare Hemophilia Factors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. United Kingdom Rare Hemophilia Factors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Russia Rare Hemophilia Factors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Italy Rare Hemophilia Factors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Asia-Pacific Rare Hemophilia Factors Sales Market Share by Type (2016-2026)
Figure 58. Asia-Pacific Rare Hemophilia Factors Sales Market Share by Application (2016-2026)
Figure 59. Asia-Pacific Rare Hemophilia Factors Revenue Market Share by Region (2016-2026)
Figure 60. China Rare Hemophilia Factors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan Rare Hemophilia Factors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. South Korea Rare Hemophilia Factors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India Rare Hemophilia Factors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia Rare Hemophilia Factors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia Rare Hemophilia Factors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America Rare Hemophilia Factors Sales Market Share by Type (2016-2026)
Figure 67. South America Rare Hemophilia Factors Sales Market Share by Application (2016-2026)
Figure 68. South America Rare Hemophilia Factors Revenue Market Share by Country (2016-2026)
Figure 69. Brazil Rare Hemophilia Factors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Argentina Rare Hemophilia Factors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Middle East and Africa Rare Hemophilia Factors Sales Market Share by Type (2016-2026)
Figure 72. Middle East and Africa Rare Hemophilia Factors Sales Market Share by Application (2016-2026)
Figure 73. Middle East and Africa Rare Hemophilia Factors Revenue Market Share by Country (2016-2026)
Figure 74. Turkey Rare Hemophilia Factors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Saudi Arabia Rare Hemophilia Factors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. UAE Rare Hemophilia Factors Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Methodology
Figure 78. Research Process and Data Source
世界の血友病A・B組換え因子補充療法市場規模・現状・予測（2021年-2027年） Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood clotting after an injury. Internal bleeding inside the joint or inside brain is commonly seen in the patients with severe to moderate haemophilia. Its symptom…- 世界の第IX因子欠乏症治療市場規模・現状・予測（2021年-2027年） Factor IX (or Christmas factor) is one of the serine proteases of the coagulation system; it belongs to peptidase family S1. Deficiency of this protein causes hemophilia B. In this market study, analysts have estimated the prophylaxis segment to dominate the factor IX deficiency treatment market dur…
- 世界の第IX因子欠乏症治療市場 2021：企業別、地域別、種類・用途別 The Factor IX Deficiency Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade …
- 世界の抗血友病因子（AHF）・フォンウィルブランド因子（VWF）複合体市場規模・現状・予測（2021年-2027年） Antihemophilic and von Willebrand factor complex is a combination medicine used to treat or prevent bleeding episodes in people with von Willebrand disease. Antihemophilic and von Willebrand factor complex is also used to treat or prevent bleeding episodes in people with hemophilia A. Market Analysi…
- 世界の第VIII因子欠乏症治療市場規模・現状・予測（2021年-2027年） Factor VIII is an essential blood-clotting protein, which is also known as an antihemophilic factor. In individuals, factor VIII is encoded by F8 gene. Defects in F8 gene lead to hemophilia A, a recessive X-linked coagulation disorder. Factor VIII is generated in liver sinusoidal cells and endotheli…